HOPO Therapeutics
HOPO Therapeutics
Home
About
Company
People
Careers
FAQ
Our Focus Areas
Radiological Hazards
Lead Poisoning
Metals in Medicine
Our Science
Discovery & Development
HOPO-101
Publications
News
Contact
All News
HOPO Therapeutics awarded BARDA contract of up to $226 million
Oct 2, 2024
HOPO Therapeutics jointly awarded $1.78M ARPA-E Grant
Nov 2, 2023
Phase 1 Clinical Trial of HOPO 14-1 Now Recruiting
Jun 9, 2023
CEO Julian Rees named 2023 Activate Fellow
Jun 8, 2023
Launch of Phase 1 Clinical Trial for HOPO 14-1
May 15, 2023
Poets & Quants names HOPO Therapeutics a 2022 Most Disruptive MBA Startup
Dec 16, 2022
HOPO Therapeutics named as an awardee in CLS Inspire QuickFire Challenge for BIPOC Communities
Nov 25, 2022
Berkeley Haas Features HOPO & VP Hannah Weber
Oct 25, 2022
»
Cite
×
